AstraZeneca

@AstraZeneca

We are AZ’s Global Media Team, tweeting what we find interesting. AZ creates medicines that make a difference to patients...we hope our feed reflects that.

Global
הצטרף/ה ב-אוגוסט 2009

@AstraZeneca חסומ/ה

האם אתה בטוח שאתה מעוניין להציג ציוצים אלה? הצגת הציוצים לא תשחרר את החסימה של ‎@AstraZeneca.

  1. ‘AstraZeneca Exchange’ will bring together representation from industry, , academia, Government & the public sector in the

  2. Next week we’ll be hosting the first ‘AstraZeneca Exchange’ networking event at our , Sweden R&D site

  3. Dr. Sean Bohen, EVP on 'Molecular Diagnostics to Tailor Patient Treatment'

  4. Thank you for hosting another successful conference to help advance medicine!

  5. There is overlap between drivers of & other conditions associated with autoimmunity

  6. Autoimmunity is to identify & act upon common phenotypes underlying the heterogeneity of respi diseases.

  7. Last in our series of blogs, we look at applying to conditions

  8. Thinking about who to follow for coverage? Check out these 'Featured Voices' for this year's meeting

  9. Join us for this evening’s symposium on the evolving perspectives in heterogeneity.

  10. We are exploring subdivisions of epithelial pathology & disruptive strategies to target

  11. Epithelial-driven pathology typifies a more expansive approach to &

  12. This infographic illustrates exactly what happens when an exacerbation takes place

  13. Next up in our series of blogs we explore epithelial-driven pathology in

  14. We're working to transform respiratory disease and make a big difference to patients -

  15. An estimated 5-10% of people living with experience severe asthma

  16. Meetings like are crucial to enable a continued flow of treatments to help manage

  17. Type 2 immune responses offer rich source of potential targets for new therapies in asthma

  18. Happening now: Watch a 3D printer create a phospholipid at our booth 1503

  19. Our new infographic explores the growing burden of :

  20. We are focusing on T2 immune responses & other potential mediators of immune function and inflammation

  21. Here are 5 of the most common triggers of exacerbations. - which others do you see regularly?

  22. Next in our blog series is type-2 immune response in

  23. We’re defining a new approach to developing nanomedicines for therapies

  24. Stages of range from mild to very severe. Understand the characteristics of each stage:

  25. Looking forward to this evening’s symposium on the evolving science in the management of

  26. The signs and symptoms of vary from patient to patient and can be impacted by their environment

  27. Check out AZ’s Co-Suspension Technology 3D Experience at booth 1503 today at !

  28. Biological pathways illuminate triggers of so we can apply targeted medicine approaches

  29. In 80s eosinophils thought to be respi disease drivers, today they’re most recognized phenotypes

  30. What exactly is the difference between the inflammation caused by & ?

  31. Severe accounts for 50% of disease related costs

  32. Did you know that ~50% of patients have eosinophilic inflammation?

  33. Tom Keith-Roach, VP, Respiratory, Inflammation and Autoimmunity, shares what means for AZ, and for patients

  34. Learn more about the global implications of

  35. Check out the latest prevalence statistics of globally & the impact it’s having on patients’ lives

  36. Learn about the different levels of severity of exacerbations & the subsequent impact on the patient

  37. We have a new strategic framework for R&D, 4 biological pathways. Read our blog series

  38. Learn about , which correlate w/ inflammation & airway hyper-responsiveness in ~50% of patients

  39. How often do patients with visit the emergency department or hospital in an average year?

  40. San Francisco starts today! 500 sessions, nearly 7000 research abstracts/case reports - all in 1 place

  41. 315 million individuals suffer from worldwide.

  42. AZ is presenting 61 abstracts over the next few days at in San Francisco

  43. attendees can explore the lungs of a patient beginning on Sunday at booth 1503

  44. We’re looking forward to sharing the future of our portfolio at

  45. The King of Sweden uses virtual reality to see the future of molecular design during a visit to

  46. Attending ? We'll be tweeting here and with

    • @UCSF

      UC San Francisco is the leading university exclusively focused on health.

    • @BSeay05

      Pediatric Pulmonology fellow at Univ of Florida. Social media advocate. tweets are my own, not to be used as medical advice

  47. Thank you for your support in raising awareness on this !

מסתבר כי הטעינה לוקחת זמן־מה.

ייתכן שיש עומס או תקלה זמנית בטוויטר. נסה שוב או בקר בדף המצב של טוויטר לקבלת מידע נוסף.

    ייתכן שגם ימצא חן בעיניך

    ·